

Rossella Maria Bertulli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5859401/publications.pdf>

Version: 2024-02-01

44
papers

6,743
citations

172386
29
h-index

243529
44
g-index

45
all docs

45
docs citations

45
times ranked

5796
citing authors

#	ARTICLE	IF	CITATIONS
1	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet</i> , The, 2004, 364, 1127-1134.	6.3	1,561
2	Consensus meeting for the management of gastrointestinal stromal tumorsâ€ Report of the GIST Consensus Conference of 20â€21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005, 16, 566-578.	0.6	628
3	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. <i>Gastroenterology</i> , 2004, 127, 294-299.	0.6	363
4	Rhabdomyosarcoma in adults. <i>Cancer</i> , 2003, 98, 571-580.	2.0	360
5	Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. <i>Cancer</i> , 2004, 101, 627-634.	2.0	345
6	Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397.	0.8	326
7	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	5.1	270
8	Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancerâ€Italian Sarcoma Groupâ€Australasian Gastrointestinal Trials Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5795-5804.	0.8	266
9	Imatinib mesylate in chordoma. <i>Cancer</i> , 2004, 101, 2086-2097.	2.0	250
10	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	0.8	248
11	Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. <i>Cancer</i> , 2001, 92, 1259-1264.	2.0	237
12	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessmentâ€Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. <i>Radiology</i> , 2009, 251, 447-456.	3.6	198
13	Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455.	2.0	167
14	Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2112-2118.	0.8	165
15	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	0.7	141
16	Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Cancer</i> , 2013, 49, 3140-3148.	1.3	110
17	A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 5910-5916.	3.2	101
18	Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 3542-3551.	0.7	86

#	ARTICLE	IF	CITATIONS
19	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 1484-1490.	1.3	85
20	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	0.6	84
21	The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1093-1100.	0.7	78
22	Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. <i>Journal of Surgical Oncology</i> , 2003, 83, 147-153.	0.8	77
23	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	3.2	70
24	Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor \hat{I}^2 Tyrosine Kinase Receptors in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2004, 10, 938-943.	3.2	62
25	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
26	c-Kit/PDGFR α Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2369-2377.	3.2	60
27	Cytokeratin Immunoreactivity in 41 Cases of ES/PNET Confirmed by Molecular Diagnostic Studies. <i>American Journal of Surgical Pathology</i> , 2001, 25, 273-274.	2.1	60
28	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 16.	2.3	44
29	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	0.6	42
30	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. <i>European Journal of Cancer</i> , 2010, 46, 2837-2848.	1.3	30
31	Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. <i>Medical Oncology</i> , 2019, 36, 59.	1.2	24
32	Oncogenic and ligand-dependent activation of KIT/PDGFR α in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). <i>Journal of Pathology</i> , 2009, 217, 103-112.	2.1	19
33	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. <i>European Journal of Cancer</i> , 2021, 151, 150-158.	1.3	19
34	Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors. <i>Tumori</i> , 1998, 84, 558-561.	0.6	18
35	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. <i>Oncotarget</i> , 2016, 7, 75503-75517.	0.8	16
36	Unusual sites of Ewing sarcoma (ES): A retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG). <i>European Journal of Cancer</i> , 2013, 49, 3658-3665.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS2). <i>Cancer</i> , 2022, 128, 1958-1966.	2.0	12
38	Rapid-Onset Opioids for the Treatment of Breakthrough Cancer Pain: Two Cases of Drug Abuse: Table 1. <i>Pain Medicine</i> , 2014, 15, 758-761.	0.9	9
39	Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 43-53.	1.0	9
40	Primary Ewing's sarcoma of the sinonasal tract in adults: A challenging disease. <i>Head and Neck</i> , 2017, 39, E45-E50.	0.9	7
41	Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. <i>Anti-Cancer Drugs</i> , 2020, 31, 80-84.	0.7	7
42	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	0.7	6
43	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. <i>Cancer Medicine</i> , 2021, 10, 4356-4365.	1.3	6
44	Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma. <i>Anti-Cancer Drugs</i> , 2016, 27, 908-913.	0.7	1